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Abstract. 
 
The major vault protein (MVP) is the pre-
dominant constituent of ubiquitous, evolutionarily con-
served large cytoplasmic ribonucleoprotein particles of 
unknown function. Vaults are multimeric protein com-
plexes with several copies of an untranslated RNA. 
Double labeling employing laser-assisted confocal mi-
croscopy and indirect immunoﬂuorescence demon-
strates partial colocalization of vaults with cytoskeletal 
elements in Chinese hamster ovary (CHO) and nerve 
growth factor (NGF)-treated neuronlike PC12 cells. 
Transfection of CHO and PC12 cells with a cDNA en-
coding the rat major vault protein containing a vesicu-
lar stomatitis virus glycoprotein epitope tag demon-
strates that the recombinant protein is sorted into vault 
particles and targeted like endogenous MVPs. In neu-
ritic extensions of differentiated PC12 cells, there is an 
almost complete overlap of the distribution of microtu-
bules and vaults. A pronounced colocalization of vaults 
with ﬁlamentous actin can be seen in the tips of neu-
rites. Moreover, in NGF-treated PC12 cells the location 
of vaults partially coincides with vesicular markers. 
Within the terminal tips of neurites vaults are located 
near secretory organelles. Our observations suggest 
that the vault particles are transported along cytoskele-
tal-based cellular tracks.
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1. 
 
Abbreviations used in this paper:
 
 GLUT4, glucose transporter 4;
LRP, lung resistance–related protein; MVP, major vault protein; pvMVP,
plasmid encoding VSVG-tagged MVP; SV2, synaptical vesicle protein 2;
vMVP, VSVG-tagged MVP; vRNA, vault RNA; VSVG, vesicular stoma-
titis virus glycoprotein.
 
V
 
AULTS
 
, named for their morphology reminiscent of
the vaulted ceilings of cathedrals, are ubiquitous,
evolutionarily conserved large cytoplasmic ribonu-
cleoprotein particles of unknown function (for review see
Kickhoefer et al., 1996). They represent multimeric pro-
tein complexes with one predominant member, the major
vault protein (MVP).
 
1
 
 MVP has been characterized in mo-
lecular detail in human, rat, electric ray, and cellular slime
mold 
 
Dictyostelium discoideum.
 
 It was found to be highly
conserved in the animal kingdom (Vasu et al., 1993; Kick-
hoefer and Rome, 1994; Scheffer et al., 1995; Vasu and
Rome, 1995; Herrmann et al., 1997). Highly purified vault
particles derived from mammals indicate the presence of
uncharacterized minor vault proteins (
 
z
 
54, 192, and 210
kD) (Kedersha and Rome, 1986).
Vault particles also contain several copies of a structur-
ally conserved vault RNA (vRNA). vRNAs (RNA poly-
merase III products) have been cloned from humans, rats,
mice, and bullfrogs (Kickhoefer et al., 1993, 1996, 1998).
Although many molecular features of vault particles have
been characterized, the function of this large ribonucleo-
protein particle remains enigmatic. The identification of
the human MVP (initially named LRP for lung resistance–
related protein) shed new light on putative cellular func-
tioning of vaults. Numerous multidrug-resistant cancer
cells frequently overexpress LRP (Izquierdo et al., 1996)
and increased LRP mRNA expression was found to corre-
late strongly with a predictive value for a multidrug-resis-
tant phenotype (Laurençot et al., 1997). Moreover, it was
shown that the vault number is correlated directly to mul-
tidrug resistance (Kickhoefer et al., 1998).
An early postulate for vault function was nucleocyto-
plasmic transport (Rome et al., 1991; Chugani et al., 1993).
Vaults have been proposed to constitute the transporter,
or the central plugs of the nuclear pore complexes, con-
trolling bidirectional exchange between nucleus and cyto-
plasm. Regarding the cellular distribution, 
 
z
 
5% of the
vault particles are assigned as nucleus-associated and lo-
calized to the nuclear pore complex. By conventional im-
munocytochemistry, most vault particles appear to be uni-
formly distributed in a punctate pattern throughout the 
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cytoplasm in a variety of cells (Izquierdo et al., 1996).
Moreover, in rat fibroblasts clusters of vaults are localized
at tips of actin filaments in the cell periphery (Kedersha
and Rome, 1990). Upon subcellular fractionation vault
particles were originally copurified with vesicular struc-
tures (Kedersha and Rome, 1986). In the electromotor
system of 
 
Torpedo marmorata
 
, vaults are transported to
the nerve terminal where they are allocated near synaptic
vesicles (Herrmann et al., 1996; Volknandt and Herrmann,
1997).
To further elucidate the neural aspect of vaults, we an-
alyzed the distribution of vaults in NGF-differentiated
PC12 cells with various cellular markers employing laser-
assisted confocal microscopy and indirect immunofluores-
cence. The localization of vaults in neuronlike PC12 cells
was compared with vault distribution in CHO cells, a cell
line with abundant vaults but lacking the specialized neu-
ronlike cellular differentiation that can be induced in the
PC12 cell line. We describe a partial colocalization of
vaults with cytoskeletal elements. Moreover, in differenti-
ated PC12 cells location of vaults partially coincides with
vesicular markers. Transfection of CHO and PC12 cells
with a cDNA encoding the rat MVP containing the viral
peptide vesicular stomatitis virus glycoprotein (VSVG) as
a tag, demonstrates that the recombinant protein is sorted
into vault particles and targeted to the appropriate cell
destinations just like endogenous MVPs.
 
Materials and Methods
 
Construction of Expression Vectors
 
The VSVG-tag (YTDIEMNRLGK) was inserted at the NcoI site located
directly at the initiation codon at the 5
 
9
 
 end of the cDNA of rat MVP. The
resulting cDNA was cloned into the EcoRI site in the mammalian expres-
sion vector pcDNA3 (CLONTECH). The engineered construct was
named plasmid encoding VSVG-tagged MVP (pvMVP).
 
Cell Cultures
 
PC12 cells (phaeochromocytoma cells of rat adrenal medulla origin)
were grown in DME supplemented with horse serum (10%) and FCS
(5%) at 37
 
8
 
C in the presence of 5% CO
 
2
 
. CHO cells (derived from ovary
cells of the Chinese hamster, 
 
Cricetulus griseus
 
) were cultivated with
Ham’s F12 medium supplemented with FCS (10%) at 37
 
8
 
C in the pres-
ence of 5% CO
 
2
 
.
 
Transfection of PC12 and CHO Cells
by Electroporation
 
PC12 cells were rinsed carefully with 10 ml electroporation buffer (123 mM
NaCl, 5 mM KCl, 0.7 mM Na
 
2
 
HPO
 
4
 
, 6 mM glucose, 20 mM Hepes, pH
7.05). The cells were removed from the culture flask with 5 ml (two times)
electroporation buffer and centrifuged at 300 
 
g
 
 for 5 min. The supernatant
was discarded and the cell pellet was resuspended in 800 
 
m
 
l electropora-
tion buffer. For transfection, the cell suspension was mixed with 50 
 
m
 
g of
plasmid DNA in a 4-mm electroporation cuvette. After incubation for 2–5
min at room temperature, electroporation was performed with the follow-
ing parameters: 500 
 
m
 
F, 310 V, 129 
 
V
 
 (BTX, Electro cell manipulator 600;
Angewandte Gentechnologie Systeme GmbH). The transfected cells were
resuspended thoroughly in 20 ml recovery medium (PC12 cell medium as
described above supplemented with 3 mM EGTA) and incubated for 30
min at 37
 
8
 
C, 10% CO
 
2
 
. After centrifugation at 300 
 
g
 
 for 5 min, the cells
were resuspended in 14 ml of medium and grown in culture plates (diam
94 mm) for 48 h in the absence or presence of 
 
b
 
-NGF (5 ng/ml; Sigma
Chemical Co.). For immunocytochemistry, cells were transferred to
poly-
 
D
 
-lysine–coated Permanox coverslips (5 
 
m
 
g/cm
 
2
 
; Sigma Chemical
Co.) 24 h after transfection. 1 d after seeding (5.0 
 
3
 
 10
 
4
 
 cells/ml), the cells
were processed for immunocytochemistry. Transfection of CHO cells was
performed according to the protocol of PC12 cells. In contrast to PC12
cells, CHO cells were treated with a trypsin-EDTA solution (1
 
3
 
, GIBCO
BRL) for 1.5 min and resuspended in 30 ml CHO cell medium. After cen-
trifugation at 300 
 
g
 
 for 5 min, CHO cells were resuspended in 10 ml elec-
troporation buffer and centrifuged a second time using the protocol for
PC12 cells. The parameters for the transfection of CHO cells are as fol-
lows: 250 
 
m
 
F, 420 V, 129 
 
V
 
. For further stimulation of protein expression,
sodium butyrate (6 mM) was added 16 h before assaying the cells.
 
Immunoaffinity Purification of VSVG-Tagged Major 
Vault Protein (vMVP)
 
For immunoprecipitation of vMVP from CHO cells magnetic beads con-
jugated with anti–mouse IgGs (M-450; Dynal) were used. The anti-VSVG
IgG1–coated beads were prepared as follows: 10
 
8
 
 beads were washed in
500 
 
m
 
l PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na
 
2
 
HPO
 
4
 
, 1.4 mM
KH
 
2
 
PO
 
4
 
, pH 7.4) containing 0.1% BSA. Beads were resuspended in 1 ml
PBS/0.1% BSA and incubated with 2 
 
m
 
l of anti-VSVG antibody (clone
P5D4; Sigma Chemical Co.) for 30 min at room temperature. To remove
excess antibody, beads were subsequently washed six times in 1 ml of
PBS/0.1% BSA and stored at 4
 
8
 
C overnight.
CHO cells (4 tissue culture dishes of 143 cm
 
2
 
) transfected with the
pvMVP plasmid were grown for 48 h. All subcellular fractionation steps
were carried out at 4
 
8
 
C. After removal of media, cells were washed twice
(5 ml/dish) in buffer A (150 mM NaCl, 1 mM EGTA, 0.1 mM MgCl
 
2
 
, ad-
justed to pH 7.4 with 10 mM Hepes/NaOH). Cells were mechanically de-
tached using a cell scraper in buffer A (3 ml/dish) containing a cocktail of
the following protease inhibitors: antipain, leupeptin, chymostatin (2 
 
m
 
g/
ml each), pepstatin (1 
 
m
 
g/ml), and benzamidine (1 mM). Culture dishes
were rinsed again with 1 ml of buffer A containing the protease inhibitors.
Cell suspensions were centrifuged for 5 min at 375 
 
g
 
 yielding a pellet frac-
tion (P1) and a supernatant fraction (S1); the latter was stored on ice.
P1 was resuspended in buffer A containing the protease inhibitors and
thoroughly homogenized by 12 (up and down) strokes in a 0.5-ml glass-
Teflon™ homogenizer.
The homogenate was centrifuged for 5 min at 1,000 
 
g
 
 to yield a postnu-
clear supernatant (S2). A large amount of intracellular organelles of CHO
cells was contained in the supernatant fraction (S1) resulting from a
plasma membrane disruption upon detachment of cells. Therefore, S1 was
subjected to high speed centrifugation (60 min at 180,000 
 
g
 
) to yield the
microsomal fraction, P3. P3 was homogenized in 300 
 
m
 
l of buffer A con-
taining the protease inhibitors and combined with S2. The pooled frac-
tions were layered on top of a linear sucrose gradient (4.8 ml, ranging
from 0.2 to 1.6 M sucrose) and centrifuged for 60 min at 150,000 
 
g
 
 in a
swinging bucket rotor. Fractions of 300 
 
m
 
l were collected starting from the
top of the gradient. The pooled fractions 7–9 (parent fraction) were used
for immunoisolation.
Isolation protocol was applied according to the manufacturer’s instruc-
tions. In brief, anti-VSVG IgG1–coated beads were incubated for 1 h at
4
 
8
 
C with the vault-containing fractions. Beads were washed three times
with 500 
 
m
 
l PBS/0.1% BSA. Elution of the immunocomplex was per-
formed in 30 
 
m
 
l of sample buffer (1% glycerol, 2% SDS, 0.0012% bro-
mophenol blue, 0.1 M dithiothreitol, 80 mM Tris/HCl, pH 6.8) by boiling
for 5 min in a water bath. Identically treated nontransfected CHO cells
served as a control.
 
Immunocytochemistry
 
The cellular localization of MVP was investigated using the affinity-puri-
fied polyclonal antibody against rat MVP (dilution 1:25; Kedersha and
Rome, 1986). The anti-VSV–glycoprotein mAb (1:100; V-5507; clone
P5D4; Sigma Chemical Co.) was used to detect the tagged MVP. To com-
pare the cellular distribution of rat MVP with synaptic vesicle markers
and cytoskeletal elements the following antibodies and reagents were
used: antibody against synaptophysin (1:50; pAb, G95; gift of Dr. Rein-
hard Jahn, Göttingen, Germany); antibody against VAMP-II/synaptobre-
vin-2 (1:100; mAb clone 69.1; Synaptic Systems); antibody against the syn-
aptic vesicle protein, SV2 (1:10; mAb, ascites fluid; clone CKK10H, a gift
from Dr. Regis B. Kelly, San Francisco, CA; Herrmann et al., 1996); R820,
pAb against glucose transporter 4 (GLUT4; 1:50; donated by Dr. Bonze-
lius, Frankfurt; Herman et al., 1994); 
 
b
 
-tubulin (1:40; clone 2-28-33); and
phalloidin coupled with TRITC (1:40; both Sigma Chemical Co.) to detect
F-actin.
Before fixation the living cells cultivated on Permanox chamber slides 
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(Nunc) were washed twice with Ringer’s solution (155 mM NaCl, 5 mM
KCl, 2 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 2 mM NaH
 
2
 
PO
 
4
 
, 10 mM glucose, 10 mM
Hepes buffer, pH 7.2) at 37
 
8
 
C for 1 min each. The cells were fixed for
7 min in methanol at 
 
2
 
20
 
8
 
C and rinsed three times (5 min each) with PBS
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na
 
2
 
HPO
 
4
 
, 1.4 mM KH
 
2
 
PO
 
4
 
, pH 7.4).
To prevent nonspecific binding of antibodies cells were incubated for
20 min with 5% BSA (Sigma Chemical Co.) in PBS. Primary antibodies
were applied for 20 min in the presence of 1% BSA in PBS. After three
rinses in PBS for 5 min each, secondary antibodies coupled with fluores-
cein (1:100; FITC) or rhodamine (1:50; TRITC; both Sigma Chemical Co.)
were applied under the same conditions. Finally, the cells were washed
three times with PBS (5 min each). The cells were analyzed by using an
Axiophot microscope (Zeiss) or a laser-assisted (TCS4D; Leica GmbH)
true confocal scanner.
 
Electrophoretic Techniques
 
SDS-PAGE was carried out on minigels (10% acrylamide). Immunoblot-
ting was performed using the enhanced chemiluminescence system (ECL;
Amersham) according to the manufacturer’s instructions.
 
Northern Blot Analysis
 
For analyzing length and yield of MVP transcripts, mRNA from CHO or
PC12 cells was isolated using an mRNA kit (Oligotex Direct; Quiagen).
To further investigate the influence of the differentiation state on the ex-
pression of the MVP transcript, PC12 cells were cultivated for 3 d in the
presence of 
 
b
 
-NGF (5 ng/ml; Sigma Chemical Co.). In addition, mRNA
from CHO cells transfected with pvMVP and stimulated with 6 mM bu-
tyrate was isolated. mRNA (800 ng each) was separated on a 1% agarose-
formaldehyde gel, transferred onto Hybond filters (Amersham Pharmacia
Biotech), and hybridized at 68
 
8
 
C in the presence of 5
 
3
 
 SSC (0.75 M NaCl,
75 mM sodium citrate, pH 7.0) overnight. A 2.2-kb DIG-labeled RNA de-
duced from the 3
 
9
 
 end of a rat MVP cDNA clone, isolated from a rat brain
Uni-ZAP XR library (Stratagene), was used as a probe. A 1.5-kb DIG-
labeled RNA probe, deduced from a mouse 
 
b
 
-actin cDNA clone (Strat-
agene), was used as a control.
 
Results
 
Vault Particles Are Abundant in CHO and PC12 Cells
 
Vaults have been found in all eukaryotic cells analyzed so
far with the exception of yeast. The MVP, the predomi-
nant member of vaults contributing to 
 
.
 
70% of their
mass, is abundant both in CHO and PC12 cells. By West-
ern blot analysis using the polyclonal anti–rat vault anti-
body, one protein band of 104 kD is specifically detected
in the total cell homogenates of both cell lines at a similar
level (Fig. 1 A). The antibody raised against rat vaults rec-
ognizes the MVP in all species investigated; from 
 
Dictyo-
stelium
 
 to humans with molecular masses ranging from 92
to 110 kD (Kedersha et al., 1990; Kickhoefer et al., 1996)
indicating a high conservation of the protein. As judged by
immunodetection the level of MVP in PC12 cells seems to
remain constant over 14 d of culturing time. Moreover, the
amount of MVP and its corresponding transcript in PC12
cells appear to be independent of NGF-induced differenti-
ation as estimated by Western and Northern blot analyses
(not shown).
In contrast to the yields of immunodetected protein, the
expression level of the MVP transcript, as revealed in
Northern blots, seems to be much higher in PC12 than in
CHO cells (Fig. 1 B). To verify that equal amounts of
intact mRNA from both cell lines were loaded, the hy-
bridization signal of the 
 
b
 
-actin transcript is shown for
comparison (lower panel). In this context it is noteworthy
to state that in PC12 cells the 2.2-kb RNA probe of a
 
rat MVP cDNA clone (comprising 75% of open reading
frame from the 3
 
9
 
 end) labels several additional bands al-
beit less intensely. This hybridization pattern was con-
firmed in several experiments and did not differ in NGF-
treated and untreated PC12 cells (not shown). That the
stronger recognition of the MVP-transcript in PC12 cells
as compared to CHO cells is not only due to the usage of a
rat mRNA probe is revealed in Northern blots using an
electric ray mRNA probe yielding a strong hybridization
signal with the PC12 MVP transcript (not shown). Thus,
signal strength might indeed represent a higher expression
level in PC12 than in CHO cells. In the human neuroblas-
toma cell line, SH-SY5Y, the amount of MVP transcript is
lower as compared to PC12 cells and equals that of CHO
cells (not shown). Furthermore, MVP transcript size is
considerably larger in PC12 than in CHO cells (4.9 versus
3 kb). An MVP transcript size of 4.9 kb was also found in
rat brain and human neuroblastoma cells (not shown). In
 
T. marmorata
 
 the MVP transcript size was 
 
z
 
2.8 kb (Herr-
mann et al., 1997). The cDNA clones isolated for sequenc-
ing rat, electric ray, or slime mold MVP were 
 
z
 
2.8 kb in
size. A correlation between differences in size and amount
of MVP transcripts in various species is not conclusive.
Figure 1. Expression of MVP in CHO and PC12 cells. (A) West-
ern blot of total protein extracts of CHO (lane 1) and PC12 (lane
2) cells using polyclonal affinity-purified anti–rat vault antibody.
50  mg of protein was loaded per lane. (B) Northern blot of
mRNA isolated from CHO (lane 1) and PC12 (lane 2) cells using
a DIG-labeled RNA encoding rat MVP as a probe. 800 ng of
mRNA was applied per lane. The hybridization signal for b-actin
(lower graph) served as a control. Sizes of RNA markers are indi-
cated (left). Immunocytochemistry of CHO (C) and PC12 (D)
cells using the same antibody as in B demonstrated the overall
distribution of vault particles. In D, localization of vaults in neu-
ritic extensions and tips is indicated (arrows). Bar, 20 mm. 
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Immunocytochemical analysis demonstrates the abun-
dance of MVP in both cell lines (Fig. 1, C and D). MVP is
almost uniformly distributed throughout the entire cyto-
sol. In differentiated PC12 cells labeling of MVP can also
be detected in the neuritic extensions including their tips
(Fig. 1 D, arrows).
 
Partial Overlap of Vault and Microtubule Distribution 
in CHO and PC12 Cells
 
In double labeling experiments the resolution obtained
by conventional indirect immunofluorescence technique
proved to be limited. Therefore, we analyzed the cellular
distribution of vaults by confocal laser scanning micros-
copy with 20 serial sections analyzed per cell. Double la-
beling of CHO cells using antibodies against MVP and
 
b
 
-tubulin demonstrates that vaults are often colocalized
with microtubules (Fig. 2, A and B). Vaults reveal a dis-
crete and punctate distribution throughout the cytoplasm
(Fig. 2, A and D). The distribution of 
 
b
 
-tubulin resembles
the typical fiber system of microtubules (Fig. 2, A and B,
right). There is a considerable overlap in the distribution
of the cytoskeletal fibers and vault particles. High mag-
nification of the cell periphery of CHO cells indicates a
predominant orientation of vaults along the cytoskeletal
tracks of microtubules (Fig. 2 B). Similarly, in differenti-
ated PC12 cells treated with NGF for 72 h the distribution
of MVP overlaps with that of 
 
b
 
-tubulin (Fig. 2 C). Espe-
cially in the neuritic extensions, the distribution of vaults
and microtubules appears to be similar. Staining intensity
for 
 
b
 
-tubulin in neurites of PC12 cells appears very strong,
indicating a dense packaging of microtubules. The evalua-
tion of a putative colocalization of vaults and microtubules
remains limited to the soma of PC12 cells where the local-
ization of single particles and fibers can be differentiated.
There the majority of vaults are located in the vicinity of
microtubules (Fig. 2 C, left).
 
Overlapping Distribution of Vaults and Filamentous 
Actin in Neuritic Tips of Differentiated PC12 Cells
 
The distribution of MVP- and phalloidin-stained filamen-
tous actin in CHO cells is clearly different. Whereas vaults
reveal a punctate pattern in thousands of loci throughout
the cytoplasm, the actin-based stress fibers are concen-
trated at the ruffling edges of lamellipodia and span the
entire cell as long filaments (Fig. 2 D). In the cell periph-
ery, only a partial overlap of vault and actin filament local-
ization can be observed. Similarly, in differentiated PC12
cells the distribution of vaults and actin filaments differs in
the cell soma (Fig. 2 E). However, there is an apparent
identical staining pattern of MVP and actin in PC12 cells
that is restricted to the most distal areas of neuritic exten-
sions including the tips (Fig. 2 E, inset).
 
Heterologous Expression of vMVP in CHO and
PC12 Cells
 
To analyze the sorting and targeting of MVP in a narrow
time window and to perform further double labeling ex-
periments, we engineered a construct coding for MVP and
an additional epitope recognized by an mAb. Transient
transfection of CHO and PC12 cells was performed with
the plasmid pvMVP (Fig. 3 A) encoding the viral tag
VSVG attached to the NH
 
2
 
 terminus of MVP (vMVP). To
differentiate the recombinant protein from the endoge-
nous one, two antibodies were employed. The mAb di-
rected against the VSVG epitope only recognizes the re-
combinant protein, whereas the pAb against rat MVP
detects both the endogenous and the recombinant MVP.
Transfection efficacy of electroporation differed con-
siderably between CHO and PC12 cells. About 30% of
CHO cells expressed the recombinant VSVG-tagged pro-
tein, whereas only 
 
z
 
5% of PC12 cells vMVP could be de-
tected by immunocytochemistry. In CHO cells the expres-
sion of recombinant and endogenous MVP was evaluated
Figure 2. Distribution of vaults and b-tubulin or F-actin in CHO
and PC12 cells. The localization was analyzed by double labeling
and confocal microscopy of median sections using polyclonal af-
finity-purified anti–rat vault antibody, anti–b-tubulin mAb, or
TRITC-conjugated phalloidin decorating filamentous actin. (A
and B) Arrows indicate colocalization of vault particles and mi-
crotubules in CHO cells. (C) Overlapping distribution of vaults
and microtubules in differentiated PC12 cells is shown. (D) Lo-
calization of vaults and filamentous actin in CHO cells. (E) Dis-
tribution of vaults and F-actin in PC12 cells is shown. Only in
neuritic tips distribution of vaults and F-actin overlap (arrows
and inset). Bars, 10 mm. 
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by Western and Northern analyses. The amount of the
vMVP transcript is much higher than that of the endog-
enous MVP transcript (Fig. 3 B). Northern blot analysis
reveals a 3.2-kb vMVP transcript. The shift in transcript
size occurs because of the attached nucleotides encoding
the viral epitope as well as additional nucleotides re-
quired for cloning strategies of the pvMVP construct
(Fig. 3 A). Treatment of transfected CHO cells with bu-
tyrate results in a further increase of mRNA expression
(Fig. 3 B, lane 3). Consistent with the dramatic increase
of mRNA expression, de novo synthesis of transiently
expressed vMVP far exceeded the amount of endoge-
nous MVP (Fig. 3 C, top, compare lanes 1 and 2). Ac-
cordingly, butyrate treatment further stimulates synthe-
sis of vMVP (Fig. 3 C, lane 3).
 
Immunoisolation of vMVP
 
To further analyze if recombinant MVP is sorted like
endogenous MVP, we investigated the composition of
vMVP-containing particles. We immunoisolated vMVP
from pvMVP-transfected CHO cells using a anti-VSVG
mAb coupled to anti–mouse IgG–coated magnetic beads
as a solid support. A combined fraction containing the
postnuclear supernatant and microsomes derived from
transfected CHO cells (four confluent plates) was sub-
jected to high speed glycerol gradient centrifugation. As
analyzed by Western blotting the bulk of vMVP immu-
noreactivity is retained in fractions 7–9 corresponding to
12–15% glycerol (Fig. 4 A). There is no significant shift of
vMVP immunoreactivity compared to total MVP immu-
noreactivity. Total MVP immunoreactivity of pvMVP-
transfected cells seems to shift slightly to denser fractions
Figure 3. Transient expression of rat vMVP in CHO cells. (A)
Schematic drawing of the engineered construct denoted pvMVP
for heterologous expression of rat MVP in mammalian cell lines
is shown. Note that expression vector and cDNA sequence en-
coding MVP are not in scale. (B) Northern blot using a DIG-
labeled RNA encoding rat MVP as a probe is shown. 800 ng of
mRNA was applied per lane. Lane 1 shows mRNA isolated from
nontransfected CHO cells; lane 2 shows mRNA from CHO cells
transfected with pvMVP; and lane 3 shows mRNA from trans-
fected CHO cells treated with sodium butyrate. The hybridiza-
tion signal for b-actin (lower graph) served as a control. Arrows
indicate the position of the endogenous MVP transcript (left and
right), overexpressed vMVP, and b-actin (both right). The posi-
tion of marker RNA is given in kilobases. (C) Western blot using
total protein extract of CHO cells, polyclonal affinity-purified
anti–rat vault antibody (upper graph), or anti-VSVG mAb
(lower graph) is shown. (Lane 1) Nontransfected; (lane 2)
pvMVP-transfected, and (lane 3) pvMVP-transfected and bu-
tyrate-treated cells. 30 mg of protein was applied per lane. Pro-
tein bands detected by anti-MVP antibody (MVP*) or anti-
VSVG antibody (vMVP) are marked by arrows (right). Note, the
anti-MVP antibody detects endogenous and recombinant MVP.
The size of marker polypeptides is given in kilodaltons (left).
Figure 4. Recombinant MVP
is assembled into vault parti-
cles: subcellular fractionation
(A) and immunoprecipita-
tion of VSVG-tagged major
vault protein (B and C). (A)
Western blot analysis of the
sedimentation behavior of
vaults derived from CHO
cells on glycerol gradients is
shown. The following are
shown: (top) Immunodetec-
tion of endogenous and re-
combinant MVP (MVP*)
of pvMVP-transfected CHO
cells using the anti–rat vault
antibody; (middle) immuno-
detection of vMVP using the
anti-VSVG antibody. In the top and middle frames identical frac-
tions were applied per lane. The bottom frame shows immunode-
tection of endogenous MVP derived from nontransfected cells
using the anti–rat vault antibody. Note that both the amount of
material loaded per lane as well as the exposure time was dou-
bled in the bottom frame blot as compared to the top two (50:100 mg
protein per gradient, 2:4 min exposure time). Fractions of 300 ml
were collected from the gradient and analyzed by immunoblot-
ting. The number of fraction is indicated below the graph: start-
ing fraction on top of the gradient (1) vault-enriched fraction (8)
and bottom fraction (15). (B) Western blot and (C) silver staining
of immunoprecipitate using anti-VSVG mAb and anti–mouse
IgG-coated magnetic beads as a solid carrier (lane 1). Bands
comprising minor vault proteins are not visible. Parent fraction of
transfected cells before immunoisolation (lane 2). Immunopre-
cipitate of nontransfected CHO cells applying an identical exper-
imental procedure as for transfected cells (lane 3). Parent frac-
tion of nontransfected cells before immunoisolation (lane 4).
Positions of vMVP, BSA, and heavy chains of mouse immuno-
globulins (IgGHC) are indicated. 
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(Fig. 4 A, top, fraction 10). Thus, all vMVP is particulate
and no vMVP was found to be soluble (e.g., contained in
light fractions in the upper part of the gradient). The sedi-
mentation behavior of vMVP resembles that of endog-
enous MVP. However, some MVP immunoreactivity
smears to denser fractions. This indicates an association of
vaults with larger structures (Fig. 4 A, bottom). The lack
of immunoreactivity in this region of the gradient in the
top frame may occur because of loading less material and
a shorter exposure time. The partially purified enriched
vault gradient fractions 7–9 were used as starting material
for immunoisolation. The isolated immunocomplex con-
tained vMVP as shown by Western blot using the same
anti-VSVG antibody employed for immunoisolation (Fig.
4 B, lane 1). Immunoisolation of identically treated non-
transfected CHO cells demonstrates specificity of the anti-
body reaction (Fig. 4 B, lane 3). Silver staining of the
eluted immunocomplex reveals vMVP and the presence of
additional proteins (Fig. 4 C). The polypeptide pattern
of the immunocomplex shows coeluted immunoglobulins
(heavy chains 
 
z
 
50 kD), trapped BSA (65 kD; added to
prevent nonspecific binding), and several minor bands.
This pattern was confirmed in several independent experi-
ments.
 
Vaults Accumulate in Neuritic Tips of
PC12 Cells: Comparison with the Distribution of 
Neurosecretory Organelles
 
NGF-treated PC12 cells develop a neuronal phenotype
with neurite outgrowth and the appearance of numer-
ous synaptic vesicle-like vesicle. SV2 used as a marker for
secretory organelles such as chromaffin granules as well as
synaptic vesicle-like vesicles reveal an intense and punc-
tate distribution in the perinuclear region and in the tips of
neurites (Fig. 5 A, middle). Consistently, the synaptic vesi-
cle marker, VAMP-II/synaptobrevin-2 present within the
same organelles, displays an identical intracellular local-
ization (Fig. 5 B, middle). Double labeling for the vesicle
markers and MVP demonstrates a differential distribution
of vault particles and secretory organelles in many areas of
differentiated PC12 cells. However, in the perinuclear re-
gion and in the neurites, especially in the tips, a similar
staining pattern of vaults and vesicles could be detected
(Fig. 5, A and B, right).
 
Distribution of vMVP in CHO and PC12 Cells
 
CHO and PC12 cells analyzed by laser-assisted confocal
microscopy and double labeling technique 48 h after trans-
Figure 5. Localization of vault particles and vesi-
cle markers in CHO and PC12 cells. Distribution
of endogenous vaults and the synaptic vesicle
marker SV2 (A) and VAMP/synaptobrevin (B)
in differentiated PC12 cells is shown by double
labeling in confocal images of middle sections.
Arrows indicate colocalization of secretory or-
ganelles and vaults in neuritic tips. Arrowheads
indicate immunostained neuritic tip of adjacent
cell. An identical distribution of endogenous and
recombinant MVP (vMVP) is observed in CHO
(C) and differentiated PC12 (E) cells. Note, that
antivault antibody (MVP) recognizes both en-
dogenous and recombinant MVP, whereas anti-
VSVG mAb only detects vMVP (C and E). Ar-
rows indicate targeting of endogenous and
recombinant MVP to cell extensions. Arrow-
heads indicate processes of neighboring cells
revealing no or low expression of vMVP. (D)
Localization of vMVP as compared to GLUT4-
containing organelles is shown. Thin arrows in-
dicate the differential distribution of GLUT4
and MVP in the perinuclear region of CHO cells.
(F) Colocalization of the synaptic vesicle marker
P38/synaptophysin and vMVP in neuritic ex-
tensions of differentiated PC12 cells (arrows).
Arrowheads show the nontransfected cells. Bars,
10 mm. 
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fection with the pvMVP plasmid demonstrate a high ex-
pression of recombinant vMVP (Fig. 5, C–F, middle row).
In the transfected cell lines vMVP is distributed like the
endogenous MVP (see Fig. 5, A and B). Slight differences
in staining intensity of the two antibodies are restricted to
the perinuclear region where the recombinant protein ap-
pears to be highly concentrated, presumably due to mas-
sive de novo synthesis of vMVP and lower affinity of the
polyclonal antibody (Fig. 5, C and E, right). Staining of
the recombinant protein yields the typical distribution of
vaults with the punctate pattern throughout the cytosol.
This indicates that vMVP is sorted into vault particles and
targeted to the same cellular destinations as endogenous
MVP (Fig. 5, C–F, middle, and A and B, left). The recom-
binant protein is also transported to the cell periphery
(Fig. 5, C, E and F, middle, and A and B, left). Arrow-
heads depict neighboring cells that are either nontrans-
fected and, thus, vMVP negative (Fig. 5 F), or processes of
adjacent cells exhibiting only low expression of vMVP
(Fig. 5 E).
We compared the distribution of vaults with GLUT4
which is localized in a specific cellular subcompartment. It
characterizes a distinct class of intracellular storage vesi-
cles (named surface modifying vesicle) in fat and muscle
cells as well as in a variety of transfected cell lines
(Herman et al., 1994). A CHO cell line stably transfected
with GLUT4 was transiently cotransfected with pvMVP.
Fig. 5 D displays the high expression of vMVP as com-
pared to the constitutively expressed GLUT4. Staining for
GLUT4 shows the typical intracellular punctate pattern
concentrated in the perinuclear area (Fig. 5 D, left). The
distribution of vMVP is different from that of GLUT4-
containing vesicles. Although the distribution of vMVP
is also high in the perinuclear region, the overlap with
GLUT4 vesicles is only partial (Fig. 5 D, right). Staining
for both markers shows a punctate pattern, although the
vMVP-containing loci seem to be larger.
 
vMVP Is Targeted into Neuritic Tips of Differentiated 
PC12 Cells
 
PC12 cells transfected with pvMVP and grown in the
presence of NGF for 48 h demonstrate a high expression
of vMVP uniformly distributed throughout the cytosol
with the characteristic granular appearance (Fig. 5, E
and F, middle). Double staining with anti-VSVG anti-
body recognizing only vMVP and anti-MVP antibody de-
tecting recombinant and endogenous MVP reveals an al-
most identical distribution of immunolabeling (Fig. 5 E).
vMVP is targeted to the tips of neurites as endogenous
MVP (Fig. 5 E, arrows, compare to Fig. 5 A, arrows). A
neighboring cell with low vMVP expression is depicted
by an arrowhead. The synaptic vesicle marker P38/syn-
aptophysin present exclusively on synaptic vesicle-like
vesicle is located at the cell soma and transported to neu-
rites in differentiated PC12 cells (Fig. 5 F, left). The distri-
bution of P38/synaptophysin-containing vesicles consider-
ably overlaps with that of vMVP (Fig. 5 F, right). In
contrast to SV2 and synaptobrevin that are both localized
on chromaffin granules as well as on synaptic vesicle-like
vesicle, synaptophysin accumulates in the neurite swellings
distant to the tips (Fig. 5 F, left). An extension of an adja-
cent cell without vMVP expression is depicted by an ar-
rowhead.
 
Discussion
 
vMVP Is Sorted into Vault Particles
 
About 100 copies of MVPs are contained in one single
vault particle, whereas only a few copies of the minor con-
stituents contribute to the inventory of vaults (Kedersha
et al., 1991). MVPs share a unique domain structure con-
taining an elongated 
 
a
 
-helical COOH-terminal tail, nu-
merous phosphorylation motifs, and three repetitive ele-
ments (Herrmann et al., 1998).
Electron microscopy reveals that vaults isolated from
rat liver, electric ray, rabbit, 
 
Xenopus
 
, bullfrog, sea urchin,
and the lower eukaryote 
 
D. discoideum are similar both in
their dimensions and morphology (Kedersha and Rome,
1990; Hamill and Suprenant, 1997; Volknandt and Herr-
mann, 1997). Upon subcellular fractionation MVP is en-
tirely retained in a particulate fraction. As shown by nega-
tive staining of subcellular fractions, MVP is assembled
into intact vaults (Kedersha and Rome, 1986; Kedersha et al.,
1990; Volknandt and Herrmann, 1997; Herrmann et al.,
1998). Transient transfection of the engineered construct
encoding rat vMVP in CHO cells led to a high de novo
protein synthesis of the recombinant protein. Although
the transfection efficiency was z30%, the synthesis of the
heterologously expressed protein by far exceeded the
amount of the endogenous protein.
To further evaluate the components of vault parti-
cles containing vMVP we performed immunoisolation of
pvMVP-transfected CHO cells using the coexpressed viral
tag as target epitope. Western analysis of subcellular frac-
tions demonstrates that vMVP behaving like endogenous
MVP is exclusively present in a large complex retained in
a particulate fraction. The separation method used gave
results in fractionation according to size. Thus, vMVP is
likely to be assembled into structures with approximately
the same size as vault particles. However, the quantity of
the vMVP particles expressed precluded the analysis of
their structure using negative staining electron micros-
copy. The immunocomplex mainly consisted of vMVP, im-
munoglobulins, and most likely, trapped BSA. In addition,
we found several minor bands not characterized yet. Mi-
nor constituents of endogenous vault particles have been
reported to be proteins of 54, 192, and 210 kD as well as a
nontranslatable vRNA of 37 kD (Kedersha and Rome,
1986). Although bands of the isolated immunocomplex
migrated at the expected sizes, additional bands of similar
or even stronger intensities could not be assigned to the
pattern of vault components reported so far (Kickhoefer
et al., 1996). Thus, the composition of vMVP-containing
vaults is not conclusive.
The assembly of vault particles is probably mediated by
the elongated coiled-coil domain at the COOH terminus
of MVP (Herrmann et al., 1996). Preliminary experiments
with truncated versions of MVP indicate that the COOH
terminus is essential for vault assembly. The amount of
overexpressed vMVP might far exceed the required cellu-
lar content of the minor vault components which gives rise
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lacking the other constituents. The contribution of the mi-
nor components in highly purified vaults from various spe-
cies can vary (Kedersha et al., 1990; Herrmann et al.,
1996). Consistently, vault formation is limited by the ex-
pression of MVP (Kickhoefer et al., 1998). Vaults consist-
ing mainly of vMVP and lacking the others might be a
valuable tool to study the relevance of the minor constitu-
ents for vault function.
Cellular Distribution of Vaults in CHO and PC12 Cells
Immunocytochemical analysis of transfected CHO and
PC12 cells reveals a dense punctate pattern of MVP and
vMVP throughout the entire cytoplasm in both cell lines.
The granular cytoplasmic appearance of MVP represents
the distribution of vault particles. In rat fibroblasts, a
punctate cytoplasmic pattern of vault distribution with
thousands of vault loci has been reported (Kedersha and
Rome, 1990). Both in CHO and PC12 cells, MVP and
vMVP are targeted to the cell periphery.
Expression of vMVP is detectable 6 h after transfection
of cells. 48 h after transfection vMVP is localized in the
neuritic tips of differentiated PC12 cells identical to en-
dogenous MVP. In CHO cells stably transfected with
GLUT4 and transiently transfected with vMVP, the local-
ization of GLUT4-containing vesicles and vMVP differs.
In contrast, the distribution of MVP/vMVP-containing
vaults coincides with markers of secretory organelles in
PC12 cells. Double labeling demonstrates a partial colo-
calization of vaults and secretory organelles in the soma of
PC12 cells. Colocalization of vaults and vesicles is obvious
in neuritic tips. Markers for secretory vesicles used in this
study reside either exclusively on small electron-lucent
synaptic vesicle-like vesicles (P38/synaptophysin) or also
on large granules (SV2 and VAMP/synaptobrevin) shown
recently by immunoelectron microscopical analysis (Marxen
et al., 1997). Using the same technique and antibodies
against MVP or SV2, a high concentration of vaults and
synaptic vesicles was also found in the synaptic terminals
of Torpedo electromotoneurons near each other (Herr-
mann et al., 1996).
Vaults Are Associated with Cytoskeletal Elements
Comparison of the distribution of vaults with microtubules
in CHO cells reveals a similar pattern in corresponding
immunofluorescent images. Vault puncta seem to be ori-
ented along microtubules from the center to the cell pe-
riphery. Especially at high magnification, an overlapping
distribution of microtubules and vaults in cellular exten-
sions becomes obvious. These observations imply the pos-
sibility that vaults, as abundant cytoplasmic particles, are
contained in microdomains structurally organized by mi-
crotubules and appear to be codistributed. A comparison
of the distribution of vaults with filamentous actin in CHO
cells reveals a divergent localization. The typical granu-
lar cytoplasmic vault distribution differs remarkably from
that of polymerized actin organized in long stress fibers
and concentrated at focal adhesion points of spreading
CHO cells. In spreading fibroblasts, vaults are clustered in
localized zones within lamellipodia at actin-rich ruffling
edges (Kedersha and Rome, 1990). Furthermore, we com-
pared the distribution of vaults with microtubules or fila-
mentous actin in differentiated PC12 cells that resembled
a neuronlike cell type. Overlay of vault and microtubule
immunofluorescence in serial sections of PC12 cells yields
an almost identical localization of both structures in neu-
rites. In the soma of PC12 cells there is no apparent colo-
calization of vault particles and actin filaments. However,
in the tips of neurites the distribution of vaults and actin fi-
bers seem to overlap completely, yielding an identical pat-
tern of immunostaining. Our immunocytochemical data
suggest that there is a cellular transport of vaults mediated
by microtubules in the cell soma and neuritic extensions
and actin filaments in neuritic tips, where we found colo-
calization of vaults and secretory organelles.
It has been reported that vaults copurify with microtu-
bules in sea urchin preparations, but the two can be sepa-
rated by further fractionation. Thus vaults are not consid-
ered to be microtubule-associated proteins (Hamill and
Suprenant, 1997). The codistribution of vaults with micro-
tubules in cell soma and neurites and the occurrence of
vault particles in neuritic tips indicate regulated active cy-
toplasmic transport. In the neuritic tips, the distribution of
vaults resembles that of secretory organelles. In the elec-
tric ray, T. marmorata, vaults occur in the axon and are
abundant in nerve terminals of electromotoneurons imply-
ing active axonal transport (Herrmann et al., 1996, 1998;
Volknandt and Herrmann, 1997). The dynamic evidence is
further supported by crush experiments of the electric
nerves demonstrating time-dependent axonal transport
with anterograde and retrograde accumulation of vaults
(Li et al., 1999).
Cytoplasmic transport of membranous organelles has
been studied in a variety of cells. The nerve axon is a good
model system for studying organelle transport. Vesicular
organelles are axonally transported using microtubules
as cellular tracks and motor proteins (for review see Hi-
rokawa, 1998). In addition to the microtubule-dependent
mechanism, fast transport of organelles also occurs in the
presence of actin filaments (Kuznetsov et al., 1992). Oc-
currence of polyribosomes and different types of RNA in-
cluding mRNAs and nonmessenger RNAs in dendrites
has been reported (Steward et al., 1996a). There is evi-
dence that mRNA is transported as part of a larger struc-
ture on cytoskeletal elements (Taneja et al., 1992; Ferran-
don et al., 1994; Carson et al., 1997). Proteins encoded by
dendritic mRNA belong to diverse classes representing ki-
nases, cytoskeletal components, and receptors.
The axonal compartment of mammals has been thought
to be devoid of mRNA. Recently in the neurosecretory ax-
ons of the hypothalamo-neurohypophyseal system, mRNAs
encoding vasopressin, oxytocin, prodynorphin, and a neu-
rofilament protein species have been identified (for review
see Steward et al., 1996b, 1997). mRNA anchoring to actin
filaments (fibroblasts) and also to microtubules (neurons)
has been demonstrated (Taneja et al., 1992; Bassel et al.,
1994a,b). Reports about transport of nonmessenger RNAs
are rare. Neural BC1 RNA, a small polymerase III tran-
script of unknown function, is preferentially expressed in
the brain and is distributed to neuronal dendrites (Tiedge
et al., 1991). Moreover, BC1 RNA, a component of a 10S
ribonucleoprotein particle, is transported in hypothalamo-
neurohypophyseal axons (Kobayashi et al., 1991; Tiedge et
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RNA contains elements capable of linking a subset of
mRNAs to microtubules presumably by controlling RNA
transport along dendritic microtubules (Muramatsu et al.,
1998). Little is known concerning the transport mecha-
nisms of RNA particles. Kinesin antisense oligonucle-
otides inhibit the transport of myelin basic protein mRNA
in processes of cultured oligodendrocytes (Carson et al.,
1997). RNA was found to be associated with granules. In
cultured neurons, RNA granules were transported in an-
terograde and retrograde direction. The motility had char-
acteristics of an organelle that might be actively trans-
ported along cytoskeletal tracks (Knowles et al., 1996).
Vaults are by far the largest ribonucleoprotein particles
transported to nerve endings and neuritic tips. Our data
propose that in neuronlike cell type, vaults may have addi-
tional specialized function.
Our findings provide new insights into the cellular distri-
bution of an organelle, which recently has begun to attract
attention in different areas of cell biology. The occurrence
and abundance of this large cytoplasmic ribonucleoprotein
particle in eukaryotic cells argue for an important general
function. This is further supported by the high phyloge-
netic conservation of its main component, the MVP. Cyto-
plasmic transport of vaults may be required for the various
physiological functions postulated so far. A clinical rele-
vance of the human MVP in the prediction of multidrug
resistance phenotype in numerous cancer cell lines is well
documented. Upregulation of MVP and vaults is a predic-
tor of the multidrug resistance phenotype, but the cellular
mechanisms are not understood.
Although there is no preferential localization of vaults
to the nuclear envelope, a functional role in nucleocyto-
plasmic exchange has been proposed. An involvement of
vaults in intracellular traffic might be mediated by binding
to other cellular organelles or targets. Recently, an inter-
action of vaults with intracellular steroid hormone re-
ceptors has been reported (Abbondanza et al., 1998). The
active nucleocytoplasmic shuttle might depend on interac-
tion with members of the nuclear receptor superfamily. To
obtain insights in the regulation of intracellular transport
of vaults on cytoskeletal tracks is a future challenge. The
targeting of this large ribonucleoprotein particle to the cell
periphery implies new aspects of the functioning of vaults.
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